Castle Biosciences Inc. Common Stock
CSTLUnited States
5 filed reports · 281 financial concepts · 4 earnings calls · 0 media appearances
Filed reports
5 reports · Jun 2025 to Jun 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 4 | 1,088 | Jun 2025 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 1 | 864 | Dec 2025 |
Financial data
281 concepts · 1,952 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial263 concepts · 1,748 facts · Dec 2023 to Jun 2026
- Stockholders equity (US GAAP)14 · Dec 2023 to Jun 2026
- Adjustments to additional paid in capital sharebased compensation requisite service period recognition value13 · Dec 2023 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents13 · Dec 2023 to Jun 2026
- Issuance of common stock from vested restricted stock units and payment of employees’ taxes13 · Dec 2023 to Jun 2026
- Net income loss13 · Dec 2023 to Jun 2026
- Other comprehensive income unrealized holding gain loss on securities arising during period net of tax13 · Dec 2023 to Jun 2026
- Stock issued during period value stock options exercised13 · Dec 2023 to Jun 2026
- Allocated share based compensation expense12 · Dec 2023 to Jun 2026
- Amortization of intangible assets12 · Dec 2023 to Jun 2026
- Comprehensive income net of tax12 · Dec 2023 to Jun 2026
- Contract with customer performance obligation satisfied in previous period12 · Dec 2023 to Jun 2026
- Cost of revenue (US GAAP)12 · Dec 2023 to Jun 2026
- Depreciation12 · Dec 2023 to Jun 2026
- Equity securities fv ni unrealized gain loss12 · Dec 2023 to Jun 2026
- ESPP Contributions12 · Dec 2024 to Jun 2026
- Impairment loss12 · Dec 2023 to Jun 2026
- Income loss attributable to parent12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Interest expense nonoperating12 · Dec 2023 to Jun 2026
- Investment income interest12 · Dec 2023 to Jun 2026
- Operating income loss12 · Dec 2023 to Jun 2026
- Research and development expense12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Selling general and administrative expense12 · Dec 2023 to Jun 2026
Segment17 concepts · 180 facts · Dec 2023 to Jun 2026
- Allocated share based compensation expense12 · Dec 2023 to Jun 2026
- Clinical studies and publication costs12 · Dec 2023 to Jun 2026
- Depreciation depletion and amortization12 · Dec 2023 to Jun 2026
- Income tax expense benefit12 · Dec 2023 to Jun 2026
- Interest expense nonoperating12 · Dec 2023 to Jun 2026
- Inventory usage12 · Dec 2023 to Jun 2026
- Investment income interest12 · Dec 2023 to Jun 2026
- Net income loss12 · Dec 2023 to Jun 2026
- Personnel costs12 · Dec 2023 to Jun 2026
- Professional services12 · Dec 2023 to Jun 2026
- Revenue12 · Dec 2023 to Jun 2026
- Segment expenditure addition to long lived assets12 · Dec 2023 to Jun 2026
- Segment reporting other item amount12 · Dec 2023 to Jun 2026
- Organizational and marketing costs11 · Dec 2023 to Jun 2026
- Equity securities fv ni unrealized gain loss6 · Jun 2024 to Mar 2026
- Equity securities fv ni gain loss5 · Dec 2023 to Jun 2026
- Organizational and business development costs2 · Jun 2024 to Jun 2025
Product1 concepts · 24 facts · Dec 2023 to Jun 2026
- Revenue24 · Dec 2023 to Jun 2026
Segments
204 factsFigures broken down by business line, region, product or another axis the company reports on.
Statement business segments1 member · 180 facts
- Reportable180 · Dec 2023 to Jun 2026
Product or service2 members · 24 facts
- Dermatologic12 · Dec 2023 to Jun 2026
- Non Dermatologic12 · Dec 2023 to Jun 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
4 calls · Nov 2025 to Jul 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Jul 30, 2026
- FY2026 Q1May 6, 2026
- FY2025 Q4Feb 26, 2026
- FY2025 Q3Nov 3, 2025
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.